Liberty Global Ltd Class C vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Liberty Global Ltd Class C trades at $8.5 (market cap $3.06B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 8.3× Liberty Global Ltd Class C's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Liberty Global Ltd Class C pays none. Which is the better fit depends on your goals — on Pluang, investors hold Liberty Global Ltd Class C for 21 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| LBTYK | RPRX | |
|---|---|---|
Market Cap | $3.06B | $25.27B |
Volume | 2,508,956 | 3,671,183 |
Sector | Media | Health |
52-Week High | $12.67 | $63.96 |
52-Week Low | $8.75 | $35.44 |
Typical Hold Time | 21 Days | 1 Days |
Enterprise Value | $9.72B | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
Liberty Global (LBTYK) trades at $8.52, down 4.48% amid bearish technical signals. The stock shows mixed fundamentals with strong gross margins of 67.17% but significant net losses. Recent earnings have been volatile, with Q1 2026 beating expectations but Q2 missing. The company is progressing with strategic initiatives including the Ziggo Group spin-off planned for 2027 and an AI partnership with Sierra.
Despite current losses, analyst consensus remains bullish with a $12.67 price target, suggesting 49% upside. Key risks include execution of the Ziggo listing and sustained profitability challenges. The cash position and asset monetization provide downside support, while the planned 2027 value-unlock event represents the primary growth catalyst.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →